{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:03:34Z","timestamp":1791205414996,"version":"4.1.0"},"reference-count":60,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2008,8,13]],"date-time":"2008-08-13T00:00:00Z","timestamp":1218585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurogastroenterology Motil"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:p><jats:bold>Abstract\u2002<\/jats:bold>Asimadoline is a potent \u03ba\u2010opioid receptor agonist with a diaryl acetamide structure. It has high affinity for the \u03ba receptor, with IC<jats:sub>50<\/jats:sub>of 5.6\u2003nmol\u2003L<jats:sup>\u22121<\/jats:sup>(guinea pig) and 1.2\u2003nmol\u2003L<jats:sup>\u22121<\/jats:sup>(human recombinant), and high selectively with \u03ba\u2003:\u2003\u03bc\u2003:\u2003\u03b4 binding ratios of 1\u2003:\u2003501\u2003:\u2003498 in human recombinant receptors. It acts as a complete agonist in<jats:italic>in vitro<\/jats:italic>assay. Asimadoline reduced sensation in response to colonic distension at subnoxious pressures in healthy volunteers and in irritable bowel syndrome (IBS) patients without alteration of colonic compliance. Asimadoline reduced satiation and enhanced the postprandial gastric volume (in female volunteers). However, there were no significant effects on gastrointestinal transit, colonic compliance, fasting or postprandial colonic tone. In a clinical trial in 40 patients with functional dyspepsia (Rome II), asimadoline did not significantly alter satiation or symptoms over 8\u2003weeks. However, asimadoline, 0.5\u2003mg, significantly decreased satiation in patients with higher postprandial fullness scores, and daily postprandial fullness severity (over 8\u2003weeks); the asimadoline 1.0\u2003mg group was borderline significant. In a clinical trial in patients with IBS, average pain 2\u2003h post\u2010<jats:italic>on\u2010demand<\/jats:italic>treatment with asimadoline was not significantly reduced.<jats:italic>Post hoc<\/jats:italic>analyses suggest that asimadoline was effective in mixed IBS. In a 12\u2010week study in 596 patients,<jats:italic>chronic treatment<\/jats:italic>with 0.5\u2003mg and 1.0\u2003mg asimadoline was associated with adequate relief of pain and discomfort, improvement in pain score and number of pain\u2010free days in patients with IBS\u2010D. The 1.0\u2003mg dose was also efficacious in IBS\u2010alternating. There were also weeks with significant reduction in bowel frequency and urgency. Asimadoline has been well tolerated in human trials to date.<\/jats:p>","DOI":"10.1111\/j.1365-2982.2008.01183.x","type":"journal-article","created":{"date-parts":[[2008,8,13]],"date-time":"2008-08-13T05:04:54Z","timestamp":1218603894000},"page":"971-979","source":"Crossref","is-referenced-by-count":64,"title":["Novel pharmacology: asimadoline, a \u03ba\u2010opioid agonist, and visceral sensation"],"prefix":"10.1111","volume":"20","author":[{"given":"M.","family":"Camilleri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,8,13]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01303162"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90717-Y"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2004.00632.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.agast972120"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666080-00004"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2006.00779.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(95)02011-X"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506223322506"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199508000-00014"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(94)00275-J"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)90265-8"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199908000-00014"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2004.00513.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(97)00227-3"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-328X(96)00266-5"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)91007-5"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01345-9"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)27039-6"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2982.2000.00188.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1999.0029900388"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(97)00084-9"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000028210"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.109280000.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70226-X"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02209014"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.41.5.664"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02087560"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/chir.530060814"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb17142.x"},{"key":"e_1_2_7_31_2","first-page":"76","article-title":"Brain concentrations of asimadoline in mice: the influence of coadministration of various P\u2010glycoprotein substrates","volume":"36","author":"Bender HM","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(99)00158-X"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702497"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.2000.83.4.2209"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(98)00175-4"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.2000.83.2.963"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-15-05874.2000"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.052829"},{"key":"e_1_2_7_39_2","volume-title":"Indications: Irritable bowel syndrome and postoperative ileus. Version 5.0","author":"Asimadoline Investigator\u2019s Brochure","year":"2006"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10517-007-0046-6"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300844"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4899-04.2005"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.09.038"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.1999.00625.x"},{"key":"e_1_2_7_45_2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0022-3565(24)35292-9","article-title":"Effect of gender on anti\u2010inflammatory and analgesic actions of two kappa\u2010opioids","volume":"292","author":"Binder W","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701874"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(96)70064-1"},{"key":"e_1_2_7_48_2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0022-3565(24)37421-X","article-title":"Effects of kappa\u2010opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation","volume":"285","author":"Burton MB","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_49_2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0022-3565(24)34907-9","article-title":"Peripheral effects of the kappa\u2010opioid agonist EMD 61753 on pain and inflammation in rats and humans","volume":"290","author":"Machelska H","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_50_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0022-3565(25)20128-8","article-title":"Systemic and regional hemodynamic and biological effects of a new kappa\u2010opioid agonist, niravoline, in healthy volunteers","volume":"278","author":"Bellissant E","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00256.x"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(03)02938-X"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00360.2002"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01670.x"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01922.x"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03676.x"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.07.011"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03730.x"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300811"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2007.02.012"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0707"}],"container-title":["Neurogastroenterology &amp; Motility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2982.2008.01183.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2982.2008.01183.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T12:38:52Z","timestamp":1738327132000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2982.2008.01183.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,13]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1111\/j.1365-2982.2008.01183.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2982.2008.01183.x","archive":["Portico"],"relation":{},"ISSN":["1350-1925","1365-2982"],"issn-type":[{"value":"1350-1925","type":"print"},{"value":"1365-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,13]]}}}